查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球结直肠癌药物市场 - 2023-2030年
市场调查报告书
商品编码
1290436

全球结直肠癌药物市场 - 2023-2030年

Global Colorectal Cancer Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球结直肠癌药物市场在2022年达到136亿美元，预计到2030年将出现有利可图的增长，达到181亿美元。在2023-2030年的预测期内，全球大肠癌药物市场预计将呈现3.7%的复合增长率。

结直肠癌药物包括一系列治疗结直肠癌的治疗方案，结直肠癌会影响到结肠或直肠。这些药物抑制肿瘤生长，防止癌细胞扩散，并改善病人的治疗效果。用于治疗结肠直肠癌的主要药物类别和特定药物包括化疗、免疫疗法和其他组合药物。

此外，对牵涉到结直肠癌的特定基因突变和分子途径的识别，导致了靶向治疗的发展；研究人员正在探索结合不同药物以提高治疗效果的好处，而临床试验的开展允许对新药和治疗方案进行评估，这些因素预计将在预测期内推动结直肠癌药物。

市场动态

大肠癌药物的临床试验不断增加，在预测期内推动了全球大肠癌药物市场的增长。

2022年9月，辉瑞公司与默克公司、安诺药业和皮埃尔法布尔公司合作，赞助了BEACON CRC研究。该研究评估了encorafenib + cetuximab ± binimetinib方案与标准护理相比，对先前接受治疗的转移性结直肠癌（mCRC）患者的有效性，这些患者具有特定的基因突变，称为BRAF V600E。

随机III期BEACON研究（NCT02928224）表明，与对照组相比，encorafenib + cetuximab ± binimetinib方案改善了总生存期和客观反应率。这一发现为该联合疗法治疗BRAF V600E突变型mCRC的疗效提供了证据。

ctDNA分析表明，MAPK途径的重新激活是抑制BRAF和EGFR后的一种常见耐药机制，无论是否有MEK抑制。RAS-MEK信号通路的获得性突变在接受双重方案（encorafenib + cetuximab）治疗的患者中更常见，而接受三重方案（encorafenib + cetuximab + binimetinib）的患者中受体信号的增强更普遍。

结直肠癌药物的高成本阻碍了全球结直肠癌药物市场在预测期内的增长。

根据美国疾病控制和预防中心的数据，结直肠癌的治疗费用在所有类型的癌症中排名第二，占癌症治疗相关总费用的12.6%。

医疗服务占237亿美元，而处方药为这些费用贡献了6亿美元。此外，就口服处方药而言，发现每个病人在生命的最后一年的平均费用最大（1,400美元），其次是初始护理阶段（400美元），以及持续护理阶段（约200美元）。因此，由于上述因素，预计市场将在预测期内受到阻碍。

COVID-19影响分析

由于COVID-19大流行，结直肠癌药物市场经历了重大干扰。全球医疗系统受到影响，导致癌症筛查、诊断和治疗的延误。结直肠癌药物的临床试验也受到影响，许多试验被推迟、延迟或修改，以确保病人安全和遵守与大流行病有关的限制。

因此，新药的开发和引进速度被放慢了。此外，大流行病的经济影响给医疗系统和个人带来了财政限制，可能会影响结直肠癌药物的可负担性和可获得性。这些综合因素明显影响了结直肠癌药物市场的动态。

俄罗斯-乌克兰冲突分析

俄罗斯和乌克兰之间正在进行的冲突极大地影响了乌克兰的结直肠癌药物的供应。在冲突之前，乌克兰在很大程度上依赖俄罗斯进口药品，包括癌症药物。然而，在冲突和随后的贸易限制之后，获得这些药物的机会变得有限，导致关键药物的短缺，包括用于治疗结肠直肠癌的药物。

由于这种短缺，病人无法获得基本药物，导致治疗延误，并使用替代的、不太有效的药物。此外，进口药物的成本增加，使患者和医疗系统更难负担。乌克兰货币的贬值进一步加剧了这种情况，使从其他国家购买药品变得更加困难。

俄乌冲突对结直肠癌药物市场的影响突出了全球医药供应链的潜在脆弱性。它强调了药品供应来源多样化和发展当地制药业的重要性，以加强自给自足，减少对进口药品的依赖。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按类型分析
  • 按疗法分类
  • 按终端用户分类
  • 按分销渠道分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 结直肠癌药物临床试验的增加
    • 限制因素
      • 结直肠癌药物的高成本
    • 机会
      • 越来越多地关注开发专门针对分子特征的靶向治疗方法
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • 目前的COVID-19方案
    • 后COVID-19或未来的情况
  • 在COVID-19中的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：按类型

  • 血管内皮生长因子（VEGF）抑制剂
  • 表皮生长因子受体 (EGFR) 抑制剂
  • 程序性细胞死亡蛋白1/PD1配体1（PD1/PDL1）抑制剂
  • BRAF或MEK抑制剂
  • 酪氨酸激酶（TKI）抑制剂
  • 免疫调节剂
  • 其他

第九章：按疗法分类

  • 免疫疗法
  • 靶向治疗
  • 化疗
  • 其他疗法

第十章：按终端用户分类

  • 医院
  • 专科诊所
  • 研究机构
  • 其他

第十一章：按分销渠道分类

  • 医院药房
  • 零售药店
  • 网上药店

第十二章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第13章 ：竞争格局

  • 竞争格局
  • 产品标杆
  • 公司份额分析
  • 主要发展和战略

第十四章：公司简介

  • Genentech, Inc.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Eli Lilly and Company
  • Pfizer
  • Sanofi S.A.
  • Bristol-Myers Squibb
  • Amgen
  • Merck & Co., Inc.
  • Teva Pharmaceuticals
  • Novartis
  • GlaxoSmithKline

第十五章 ：附录

简介目录
Product Code: PH4089

Market Overview

The Global Colorectal Cancer Drugs Market reached US$ 13.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 18.1 billion by 2030. The Global Colorectal Cancer Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2023-2030.

Colorectal cancer drugs encompass a range of therapeutic options for treating colorectal cancer, which affects the colon or rectum. These drugs inhibit tumor growth, prevent cancer cells from spreading, and improve patient outcomes. The major drug classes and specific medications used to treat colorectal cancer include chemotherapy, immunotherapy, and other combination drugs.

Furthermore, the identification of specific genetic mutations and molecular pathways implicated in colorectal cancer has led to the development of targeted therapies; researchers are exploring the benefits of combining different drugs to enhance treatment outcomes and the conduct of clinical trials allows for the evaluation of new medicines and treatment regimens are the factors expected to drive the colorectal cancer drugs over the forecast period.

Market Dynamics

The increasing clinical trial for colorectal cancer drugs is boosting the growth of the Global Colorectal Cancer Drug Market during the forecast period.

In September 2022, Pfizer, in collaboration with Merck KGaA, ONO Pharmaceutical, and Pierre Fabre, sponsored the BEACON CRC study. The study evaluated the effectiveness of encorafenib + cetuximab ± binimetinib regimens compared to standard of care in patients with previously treated metastatic colorectal cancer (mCRC) with a specific genetic mutation called BRAF V600E.

The randomized phase III BEACON study (NCT02928224) demonstrated that the encorafenib + cetuximab ± binimetinib regimens improved overall survival and objective response rate compared to the control group. This finding provided evidence for the efficacy of this combination therapy in treating BRAF V600E-mutant mCRC.

The ctDNA analysis demonstrated that reactivation of the MAPK pathway is a common resistance mechanism after inhibiting BRAF and EGFR, with or without MEK inhibition. Acquired mutations in the RAS-MEK signaling pathway were more frequently observed in patients treated with the doublet regimen (encorafenib + cetuximab), while enhanced receptor signaling was more prevalent in those receiving the triplet regimen (encorafenib + cetuximab + binimetinib).

The high costs of drugs for colorectal cancer are hampering the growth of the Global Colorectal Cancer Drugs Market in the forecast period.

According to the Centers for Disease Control and Prevention, the treatment expenses for colorectal cancer rank second highest among all types of cancer, comprising 12.6% of the total costs associated with cancer treatment.

Medical services accounted for $23.7 billion, while prescription drugs contributed $0.6 billion to these expenses. Furthermore, in terms of oral prescription drugs, the average costs per patient were found to be the greatest during the final year of life ($1,400), followed by the initial care phase ($400), and the continuing care phase (approximately $200). Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The colorectal cancer drugs market has experienced significant disruptions due to the COVID-19 pandemic. Healthcare systems globally have been impacted, leading to delays in cancer screenings, diagnosis, and treatments. Clinical trials for colorectal cancer drugs were also affected, with many being postponed, delayed, or modified to ensure patient safety and comply with pandemic-related restrictions.

Consequently, the development and introduction of new drugs have been slowed down. Additionally, the economic impact of the pandemic has created financial constraints for healthcare systems and individuals, potentially influencing the affordability and accessibility of colorectal cancer drugs. These combined factors have notably impacted the dynamics of the colorectal cancer drugs market.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has significantly impacted the availability of colorectal cancer drugs in Ukraine. Before the conflict, Ukraine relied heavily on Russia to import pharmaceuticals, including cancer drugs. However, following the conflict and subsequent trade restrictions, access to these drugs became limited, leading to a shortage of critical medications, including those used to treat colorectal cancer.

As a result of this shortage, patients have been unable to access essential drugs, leading to treatment delays and the use of alternative, less effective drugs. Additionally, the cost of imported drugs increased, making them less affordable for patients and healthcare systems. The situation was further compounded by the devaluation of the Ukrainian currency, making purchasing drugs from other countries more challenging.

The impact of the Russia-Ukraine conflict on the colorectal cancer drugs market highlights the potential vulnerabilities of global pharmaceutical supply chains. It underscores the importance of diversifying the sources of drug supplies and developing local pharmaceutical industries to enhance self-sufficiency and reduce dependence on imported drugs.

Segment Analysis

The Global Colorectal Cancer Drugs Market is segmented based on type, therapy, end user, distribution channel, and region.

The vascular endothelial growth factor (VEGF) inhibitors segment is expected to dominate the market over the forecast period.

The vascular endothelial growth factor (VEGF) inhibitors segment accounted for the highest market stake, accounting for approximately 1/3rd of the colorectal cancer drugs market in 2022. Vascular endothelial growth factor (VEGF) inhibitors have several advantages in the treatment of colorectal cancer. It works by blocking the activity of VEGF, a protein that promotes the formation of new blood vessels (angiogenesis).

For instance, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second-line chemotherapy.

Additionally, VEGF inhibitors are often used in combination with chemotherapy in the treatment of colorectal cancer. Studies have shown that adding VEGF inhibitors to chemotherapy regimens improves treatment response rates and overall survival compared to chemotherapy alone. This combination therapy approach can lead to more effective tumor control and increased patient outcomes.

Geographical Analysis

The increasing acquisitions by the market players, the growing prevalence of colorectal cancer, and rising product launches by the market players dominate the North American region.

North America is expected to dominate the catheter stabilization devices market, accounting for around 1/3rd of this market, with the U.S. being the major contributor.

According to the recent Colorectal Cancer Statistics 2023 report by the American Cancer Society (ACS), there has been a notable shift in colorectal cancer trends in the United States. The report reveals that the proportion of individuals diagnosed with advanced-stage colorectal cancer (CRC) has increased from 52% in the mid-2000s to 60% in 2019.

Moreover, the diagnoses of individuals under the age of 55 have doubled from 11% in 1995 to 20% in 2019, indicating a concerning rise in colorectal cancer among younger age groups. Overall, the report estimates that in 2023, approximately 153,020 people in the United States will receive a diagnosis of colorectal cancer, and 52,550 individuals will succumb to the disease. These figures highlight the significant impact and continued threat posed by colorectal cancer.

Furthermore, on March 13, 2023, Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

Hence , the North American region is expected to hold the largest market share over the forecast period due to the above factors.

Competitive Landscape

The major global players in the market include: Genentech, Inc., Eli Lilly, and Company, Pfizer, Abbott Laboratories, Sanofi S.A., Bristol-Myers Squibb, Amgen, Bristol-Myers Squib, Merck & Co., Inc., Teva Pharmaceuticals, Novartis, GlaxoSmithKline, Onyx among others.

Why Purchase the Report?

  • To visualize the Global Colorectal Cancer Drugs Market segmentation based on the type, therapy, end user, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of colorectal cancer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Colorectal Cancer Drugs Market Report Would Provide Approximately 69 Tables, 72 Figures And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Therapy
  • 3.3. Snippet by End User
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing clinical trial for colorectal cancer drugs
    • 4.1.2. Restraints
      • 4.1.2.1. The high costs of drugs for colorectal cancer
    • 4.1.3. Opportunity
      • 4.1.3.1. Growing focus on developing targeted therapies that specifically address the molecular characteristics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • 8.4. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • 8.5. BRAF Or MEK Inhibitors
  • 8.6. Tyrosine Kinase (TKI) Inhibitors
  • 8.7. Immunomodulators
  • 8.8. Others

9. By Therapy

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 9.1.2. Market Attractiveness Index, By Therapy
  • 9.2. Immunotherapy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Targeted therapy
  • 9.4. Chemotherapy
  • 9.5. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Research Institute
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.7.1. The U.S.
      • 12.2.7.2. Canada
      • 12.2.7.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.7.1. Germany
      • 12.3.7.2. The U.K.
      • 12.3.7.3. France
      • 12.3.7.4. Italy
      • 12.3.7.5. Spain
      • 12.3.7.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.7.1. Brazil
      • 12.4.7.2. Argentina
      • 12.4.7.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.7.1. China
      • 12.5.7.2. India
      • 12.5.7.3. Japan
      • 12.5.7.4. Australia
      • 12.5.7.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Genentech, Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Eli Lilly and Company
  • 14.3. Pfizer
  • 14.4. Sanofi S.A.
  • 14.5. Bristol-Myers Squibb
  • 14.6. Amgen
  • 14.7. Merck & Co., Inc.
  • 14.8. Teva Pharmaceuticals
  • 14.9. Novartis
  • 14.10. GlaxoSmithKline

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us